Journey Medical (DERM) Long-Term Deferred Tax (2020 - 2021)

Journey Medical (DERM) reported Long-Term Deferred Tax of $8.4 million for Q3 2021, up 475.03% quarter-over-quarter from $1.5 million in Q4 2020.

Journey Medical (DERM) Long-Term Deferred Tax (2020 - 2021) Analysis & Trends

Journey Medical has reported Long-Term Deferred Tax for 2 years, with the latest figure at $8.4 million in Q3 2021.

  • For the quarter ending Q3 2021, Long-Term Deferred Tax changed N/A year-over-year to $8.4 million; the trailing twelve-month figure through Sep 2021 stood at $8.4 million (changed N/A YoY), and the FY2020 full-year result was $1.5 million, changed N/A from the prior year.
  • Long-Term Deferred Tax for Q3 2021 stood at $8.4 million, up from $1.5 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $8.4 million in Q3 2021, with the low at $1.5 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Journey Medical 168.75 Mn 141.53 Mn 9.70 Mn

Historic Data

Download Data
DateValue
Sep 30, 2021 8.36 Mn
Dec 31, 2020 1.45 Mn